Clinical Trial Search

Primary: Apnea Hypopnea Index (AHI) — 1.96; 3.73; 1.23; 4.12 events per hour — p=<0.001

Primary: SpO2 ARMS of Sensor Under Motion Conditions — 1.31 % of oxygen saturated hemoglobin

Primary: Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria — 39; 30 Participants

Primary: Timeline Followback Assessing Number of Drinks Per Week — 35.9 Drinks per week — p=0.317

Primary: Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy — -39.9; 5.4 Percent change in LDL-c — p=<0.0001

Primary: Evaluation of LASIK Flap Thickness — 105.8; 112.9 micrometers — p=.003

Primary: Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1) — 6; 55 Participants — p=<0.001

Primary: IC/BPS Symptoms Change With Overall Global Response Assessment (GRA) — 2; 1 Participants

Primary: Change in Pain Level From Baseline to 90 Minutes — 3.1; 3.3 Units on a scale

Primary: Objective Response Rate (ORR) of Participants Treated With Elotuzumab + Lenalidomide/Dexamethasone (E-Ld) — 87.5 Percentage of participants

Primary: Echocardiographic Epicardial Fat Thickness — 9.6; 7.4; 6.8; 7.5 mm

Primary: Success of DEBIRI-M1 Procedure as a Measure of Feasibility (Percentage of Successful Treatments) — 100 percentage of successful treatments

Primary: Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions) — 81.5; 38.3; 11.1; 0 Percentage of participants

Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 — 0.0961; 0.0886; -0.0075 liters — p=<0.0001

Primary: Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12) — 0.05; 16.87; 17.34; 12.66 units on a scale — p=<0.001